MarketPeel
Insider Trading Intelligence
Pricing
…
TS

Thomas Sciascia

TRVI
CHIEF SCIENTIFIC OFFICER · TREVI THERAPEUTICS, INC. · CIK 0001229946
FILING MIX · LIFETIME60%/40%
BUYS
18
SELLS
12
TOTAL VALUE
$492.0K
COMPANIES
1
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
85,000
AVG SELL PX
$2.78
TRADE KIND
SHOWING 30 / 30
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
6 backtested trades · 8 horizons · 5 pending
Forward-return performance of every backtestable P/S trade by Thomas Sciascia, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d6+16.67%+2.06%+0.73%+1.32%+1.81%—
14d6+16.67%+4.15%-1.14%+5.29%+6.89%—
30d6+16.67%+17.76%+0.94%+16.83%+17.71%—
60d6+16.67%+12.75%+4.66%+8.09%+9.77%—
90d6+33.33%+3.12%+7.10%-3.98%-4.21%—
180d6+0.00%+37.85%+11.91%+25.94%+30.62%—
1y6+0.00%+150.31%+16.25%+134.06%+145.56%—
2y6(5 pending)+0.00%+471.65%————
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
TRVI · 85,000 shares · as of Feb 19, 2026
066,950133,901200,851267,801202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 18 buys / 12 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
85,000——85,000Feb 19, 2026Feb 20, 2026 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
60,000——92,000May 31, 2025May 31, 2025 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
SALE
Chief Scientific Officer
2,631$6.60$17.4K221,373Mar 25, 2025Mar 26, 2025 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASE
Chief Scientific Officer
2,631$1.43$3.8K224,004Mar 25, 2025Mar 26, 2025 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
SALE
Chief Scientific Officer
2,631——0Mar 25, 2025Mar 26, 2025 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
32,000——32,000Mar 10, 2025Mar 12, 2025 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
116,000——116,000Feb 18, 2025Feb 20, 2025 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
SALE
Chief Scientific Officer
16,496$2.96$48.9K220,315Aug 19, 2024Aug 21, 2024 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASE
Chief Scientific Officer
16,496$1.43$23.6K236,811Aug 19, 2024Aug 21, 2024 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
SALE
Chief Scientific Officer
16,496——0Aug 19, 2024Aug 21, 2024 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
SALE
Chief Scientific Officer
18,660$2.76$51.4K220,315Aug 16, 2024Aug 16, 2024 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
SALE
Chief Scientific Officer
18,660——16,496Aug 16, 2024Aug 16, 2024 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASE
Chief Scientific Officer
18,660$1.43$26.7K238,975Aug 16, 2024Aug 16, 2024 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
SALE
Chief Scientific Officer
12,745——35,156Aug 15, 2024Aug 16, 2024 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASE
Chief Scientific Officer
12,745$1.43$18.2K233,060Aug 15, 2024Aug 16, 2024 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
SALE
Chief Scientific Officer
12,745$2.79$35.5K220,315Aug 15, 2024Aug 16, 2024 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
SALE
Chief Scientific Officer
100$2.75$275220,315Aug 14, 2024Aug 16, 2024 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASE
Chief Scientific Officer
100$1.43$143220,415Aug 14, 2024Aug 16, 2024 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
SALE
Chief Scientific Officer
100——47,901Aug 14, 2024Aug 16, 2024 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASE
Chief Scientific Officer
59,354$2.19$130.0K267,801May 29, 2024May 31, 2024 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
SALE
Chief Scientific Officer
53,368$2.55$136.1K214,433May 29, 2024May 31, 2024 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
SALE
Chief Scientific Officer
59,354——0May 29, 2024May 31, 2024 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
150,000——150,000Feb 15, 2024Feb 16, 2024 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
187,500——187,500Feb 16, 2023Feb 16, 2023 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
7,500——37,500Sep 19, 2022Sep 19, 2022 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
30,000——30,000Jun 29, 2022Jun 29, 2022 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
110,000——110,000Feb 11, 2022Feb 15, 2022 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
110,000——110,000Feb 11, 2022Jul 1, 2022 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
50,000——50,000Feb 17, 2021Feb 19, 2021 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
60,000——60,000Feb 13, 2020Feb 18, 2020 ↗View →
Other insiders · TRVI
Loading peer insiders…
About this filer
CIK 0001229946
ROLE
Chief Scientific Officer
PRIMARY
TRVI
COMPANIES
1
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001229946DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback